Page Views: 274 Date Added: 05/18/2011 Last Updated: 05/18/2011 Expiry Date: 05/15/2021 Product/Service Details Zenapax is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids. General Information : Hoffman-La Roche’s new monoclonal antibody drug, Zenapax (daclizumab), has been approved to prevent rejection of kidney transplants. The drug uses the body’s own immune system to prevent the acute rejection that can make kidney transplants fail. Clinical Results. It is marketed by Hoffman La Roche pharmaceuticals. The FDA said its approval was based on two clinical trials that showed Zenapax significantly reduced acute rejections in patients who got the drug along with the standard three-drug cocktail of immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer rejections episodes than those given an inert placebo.

Company Information (3S Corporation)

Company Profile: 3s Corporation is a bulk dealer and wholesaler for oncology products and anti-cancer drugs and injections from India. We supply large quantities of drugs and medications to major markets like UK, Europe, America and Africa.. >> More Website URL: http://www.bridgat.com/u37137